Loading...
NPI 1215917588 · Lake Charles, LA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
The Pathology Laboratory, Inc. is a clinical medical laboratory provider located in Lake Charles, Louisiana. This profile covers 176 Medicare and 165 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | The Pathology Laboratory, Inc. |
| Address | 830 W Bayou Pines Dr |
| City | Lake Charles |
| State | LA |
| ZIP | 70601 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | January 20, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $13.7M |
| Medicare | $1.6M |
THE PATHOLOGY LABORATORY, INC. presents as a full-service clinical medical laboratory with heavy surgical pathology and cytopathology activity plus broad infectious/molecular testing; Medicare top codes include 88305, 88342 and 88341 while Medicaid top codes include 88305, 88175, 87491, 87591, 87661 and U0004, indicating a mix of pathologist-read specimens, high-volume cervical cytology and nucleic-acid amplified STI testing alongside routine panels and COVID testing. The code mix points to both manual pathologist interpretation capacity (multiple high-level 88xxx surgical pathology and cytology codes) and sizable molecular/automated-screening throughput for public-health relevant assays.
Revenue concentration is material on both payers: the top 3 Medicare codes account for 53.3% of the provider’s Medicare revenue and the top 3 Medicaid codes account for 44.0% of Medicaid revenue. Notably, Medicare shows a single dominant code 88305 at $520K (40.9% of Medicare revenue) while Medicaid’s 88305 drives $3.5M (28.9% of Medicaid revenue), highlighting reliance on a small set of high-yield pathology and cytology services.
Payer mix is Medicaid-dominant in scale: reported lifetime Medicaid revenue is $13.7M versus $1.6M in Medicare, so Medicaid is the primary revenue source by a large margin. This distribution suggests operational orientation toward Medicaid-reimbursed services and patient populations rather than Medicare-heavy practice.
National competitive standing on Medicare is unusually strong for several pathology codes: 88305 is listed as an "extreme outlier" nationally (ranks #69 of 14580 providers nationally, 100th percentile) and both 88342 and 88341 are similarly characterized as extreme outliers (99th percentile). Additional Medicare codes such as 88307 and G0416 also rank well above typical national volume, indicating an atypically large national footprint for selected pathologist-read procedures.
State-level competitive standing on Medicaid shows dominant in-state positions for screening and STI testing: 88175 ($922.7K) ranks #1 of 32 providers in-state (100th percentile; extreme outlier) and 88141 ($341.8K) ranks #1 of 20 providers in-state (100th percentile). 88305 is also a leading in-state code at $3.5M (ranks #3 of 92, 98th percentile), and several NAAT STI codes (87491, 87591, 87661) are ranked in high percentiles, underscoring this lab’s central role in Louisiana’s cytology and public-health testing ecosystem.
Operational implications from the code mix include substantial investment in both pathologist time and automated/molecular platforms: high-volume codes for Pap screening (88175, 88141), HPV testing (87624), CT/GC NAATs (87491, 87591), Trichomonas NAAT (87661) and COVID PCR/HT platforms (U0004, U0005) imply large batch-processing and reporting capacity, while recurring high volumes of 88305/88307 indicate ongoing demand for surgical pathology sign-out. This combination suggests the lab supports both clinic-based screening workflows and referral surgical-pathology workloads.
Concentration of revenue in a few codes and heavy Medicaid weighting create both risk and negotiating leverage: dependence on a handful of high-volume codes (precomputed top‑3 shares: 53.3% Medicare, 44.0% Medicaid) means reimbursement changes, shifts in screening guidelines, or referral pattern changes could materially affect revenue, but the provider’s top in-state rankings on key cytology and STI codes also provide bargaining power for volume-based contracts or public health agreements. Specific single-code exposures — for example, Medicaid 88305 at $3.5M — warrant attention in payer contracting and utilization review.
Tenure and market embedding: the NPI was enumerated 2006-01-20 (~20 years ago), indicating long-standing operation. Combined with the provider’s high national percentiles on several Medicare pathology codes and multiple #1 or top‑3 in-state rankings on Medicaid codes, the lab appears to be an established, high-volume regional player with entrenched relationships driving sustained specimen volume.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
176 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 20,800 | $30 | $520K |
| 88342 | The lab analyst applies an initial single antibody stain on a slide or slides prepared from a single patient specimen, such as tumor tissue. Then a qualified provider, typically a pathologist,… | 2,880 | $30 | $83.4K |
| 88341 | The lab analyst applies an additional single antibody stain on a slide or slides prepared from the same patient specimen as the initial antibody stain, such as tumor tissue. Then a qualified… | 3,060 | $20 | $73.3K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 2,870 | $20 | $45.9K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 4,400 | $10 | $44K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 4,990 | $10 | $39.9K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 4,950 | $10 | $39.6K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 3,020 | $10 | $39.2K |
| 88307 | The physician, typically a pathologist, performs a level V examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 630 | $60 | $38.7K |
| 88173 | The lab analyst performs the technical lab test to analyze a cytopathology specimen from a fine needle aspirate and then interprets and reports the results. | 610 | $50 | $32.5K |
Showing 1–10 of 176
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 176 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
176 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| U0004 | 2 | 10 | 11,140 | $70 | $818.4K |
| 87798 | 21 | 20 | 1,390 | $30 | $352.3K |
| 87481 | 12 | 20 | 270 | $30 | $82.9K |
| U0005 | 7 | 10 | 460 | $20 | $78.3K |
| G0145 | 3 | 10 | 1,100 | $30 | $25.9K |
| 88305 | 1 | 220 | 370 | $30 | $22.3K |
| 80307 | 77 | 90 | 140 | $60 | $18K |
| G0144 | 1 | 10 | 420 | $40 | $17.9K |
| 87801 | 7 | 10 | 200 | $70 | $16.9K |
| 87624 | 3 | 10 | 390 | $30 | $13.5K |
Showing 1–10 of 176
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
165 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 59,890 | $60 | $3.5M |
| 88175 | The lab analyst performs the technical lab test to analyze a cervical or vaginal cytopathology specimen that a clinician collected in preservative fluid. The test uses automated thin layer… | 65,900 | $10 | $922.7K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 38,760 | $20 | $891.5K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 37,050 | $20 | $852.1K |
| 88307 | The physician, typically a pathologist, performs a level V examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 8,000 | $90 | $688.2K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 31,610 | $20 | $569.1K |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 21,700 | $20 | $433.9K |
| 87624 | The lab analyst performs a test to determine the presence of human papillomavirus, or HPV. The provider uses nucleic acid detection for high–risk types and produces a pooled result. | 15,780 | $30 | $410.2K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 9,300 | $40 | $409.4K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 5,900 | $70 | $407.2K |
Showing 1–10 of 165
How this provider's Medicaid billing volume and revenue compare to other Louisiana providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Louisiana median
165 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 2 | 20 | 490 | $160 | $855.8K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 3 | 90 | 1,270 | $50 | $375.3K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 6 | 50 | 530 | $20 | $237.6K |
| 88307 | The physician, typically a pathologist, performs a level V examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 4 | 30 | 1,080 | $70 | $229.4K |
| 81514 | The lab analyst performs the technical lab tests on a vaginal fluid specimen for quantitative real–time amplification of DNA markers for six bacterial species listed in the code descriptor, and… | 15 | 20 | 360 | $120 | $201.8K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 38 | 170 | 1,360 | $30 | $190K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 5 | 190 | 1,000 | $30 | $139.9K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 4 | 20 | 130 | $40 | $137.4K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 5 | 190 | 900 | $30 | $137.2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 16 | 50 | 1,310 | $10 | $136K |
Showing 1–10 of 165
Other providers in the same ZIP code as The Pathology Laboratory, Inc., ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.